pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›HYDROCODONE BITARTRATE AND ACETAMINOPHEN
drug · small molecule
save

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

updated 3mo ago
by $IGC IGC Pharma, Inc.🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval7,790 co-mentions · 1766 sources
  • tagSmall Molecule3,894 co-mentions · 1765 sources
  • drugHYDROCODONE BITARTRATE AND IBUPROFEN1,611 co-mentions · 537 sources
  • drugHYDROCODONE BITARTRATE1,611 co-mentions · 537 sources
  • drughydrocodone bitartrate ER1,611 co-mentions · 537 sources
  • drugcodeine1,153 co-mentions · 591 sources
  • drugPROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE1,124 co-mentions · 562 sources
  • drugPROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE1,124 co-mentions · 562 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 18 approved and 81 investigational indications.

targets

CyclooxygenaseFatty-acid amide hydrolase 1Transient receptor potential cation channel subfamily V member 1

all catalysts(0)

nothing on the calendar yet

Trials studying HYDROCODONE BITARTRATE AND ACETAMINOPHEN

  • phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)recruitingn=770
  • phase3A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritisactive not recruitingn=271
  • phase1A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnantnot yet recruitingn=40
  • phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340
  • phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participantsrecruitingn=40
  • phase3A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Painnot yet recruitingn=60
  • phase1A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesityrecruitingn=50
  • phase2A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)recruitingn=230
more trials →

News(2)

  • STAT+: TrumpRx adds generic drugs
    A deal with Mark Cuban, Amazon Pharmacy, and GoodRx is boosting TrumpRx's offerings.
    stat · 3mo ago
  • STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA
    Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.
    stat · 3mo ago
brand
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
trade names
Abdine, Acephen, Acetaminophen, Acetaminophen component of allay, Acetaminophen component of anexsia, Acetaminophen component of anoquan
generic
ACETAMINOPHEN
MOA
Mechanism of Action Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid (µ) receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with hydrocodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.
indication
INDICATIONS AND USAGE Hydrocodone Bitartrate and Acetaminophen Tablets, USP are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see WARNINGS ] , reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Hydrocodone bitartrate and acetaminophen tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 36m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?